-
13 hours ago | 
targetedonc.com | Tim Cortese
Nivolumab (Opdivo) combined with relatlimab displayed intracranial effectiveness in patients with melanoma brain metastases whose disease had progressed despite prior anti-PD-(L)1 therapy. However, additional data is necessary to firmly establish its efficacy, according to findings from the phase 1/2a RELATIVITY-020 trial (NCT01968109) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
1 day ago | 
cancernetwork.com | Tim Cortese
Thoracic radiotherapy twice daily at a dose of 60 Gy in 40 fractions prolonged survival and was well tolerated compared with a dose of 45 Gy in 30 fractions in patients with limited-stage small cell lung cancer (SCLC), according to a phase 2 trial (NCT02041845) published in the Journal of Thoracic Oncology.1Overall, the median overall survival (OS) was 33.3 months, with 34.1% of patients alive after 5 years.
-
3 days ago | 
targetedonc.com | Tim Cortese
The addition of daratumumab (D; Darzalex) to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) led to better efficacy without compromising safety for the treatment of patients with newly diagnosed multiple myeloma, according to results from the phase 2 ADVANCE trial (NCT04268498) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 In the intention-to-treat population, the minimal residual disease (MRD) negativity of 10-5 assessed by...
-
3 days ago | 
cancernetwork.com | Tim Cortese
Receipt of 6 or more cycles of induction chemotherapy led to significantly prolonged progression-free survival (PFS) and overall survival (OS), enhancing the efficacy of first-line atezolizumab (Tecentriq) combined with chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC), according to results from a retrospective analysis published in Translational Lung Cancer Research.
-
4 days ago | 
cancernetwork.com | Tim Cortese
The European Commission (EC) has approved brentuximab vedotin (Adcetris) in combination with ECADD—etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone—as a treatment for adult patients with newly diagnosed stage IIb with risk factors, stage III, and stage IV Hodgkin lymphoma, according to a press release from the developer, Takeda.1 Previously, in April 2025, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the combination for...
-
4 days ago | 
onclive.com | Tim Cortese
The addition of daratumumab (Darzalex) to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Dara-KRd) improved rates of minimal residual disease (MRD) negativity vs KRd alone in patients with newly diagnosed multiple myeloma, independent of transplant eligibility, according to findings from the phase 2 ADVANCE trial (NCT04268498) presented at the 2025 ASCO Annual Meeting.1 In the intention-to-treat population, MRD negativity at a threshold of 10–5 assessed by next-generation...
-
4 days ago | 
cancernetwork.com | Tim Cortese
The FDA has approved darolutamide (Nubeqa) in the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC), according to a press release from the FDA.1 Previously, the FDA approved darolutamide combined with docetaxel in mCSPC.2 Supporting results from the approval came from the randomized phase 3 ARANOTE trial (NCT04736199) that evaluated the efficacy and safety of darolutamide vs placebo; all patients received a gonadotropin-releasing hormone analog concurrently or...
-
4 days ago | 
cancernetwork.com | Tim Cortese
Adding daratumumab (D; Darzalex) to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) improved efficacy without compromising the known safety profile of all involved agents in the treatment of patients with newly diagnosed multiple myeloma, according to results from the phase 2 ADVANCE trial (NCT04268498) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 In the intention-to-treat population, the minimal residual disease (MRD) negativity...
-
4 days ago | 
targetedonc.com | Tim Cortese
Frontline treatment with dostarlimab-gxly (Jemperli) and platinum-based chemotherapy with maintenance niraparib (Zejula) led to a statistically significant—though clinically modest—improvement in progression-free survival (PFS) with expected safety profile in patients with newly diagnosed advanced ovarian cancer, based on results from the phase 3 FIRST/ENGOT-OV44 trial (NCT03602859) shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 Results from the trial were...
-
4 days ago | 
oncnursingnews.com | Tim Cortese
Imlunestrant monotherapy and combination therapy with abemaciclib (Verzenios) yielded better patient-reported outcomes (PROs) in the all-oral treatment of patients with estrogen receptor (ER)–positive, HER2-negative advanced breast cancer whose disease progressed after endocrine therapy, per data from the phase 3 MEBER-3 trial (NCT04975308) shared at the 2025 ASCO Annual Meeting.
